TSAAI 2023 Annual Meeting

August 11, 2023 to August 13, 2023

TSAAI's 2023 Annual Meeting seeks to educate allergists on a variety of topics relevant to the treatment of allergy, asthma, and immunology. Join us and our nationally recognized speakers to learn more about Peanut AIT, EoE, Asthma and the role of biologics, Atopic Dermatitis, Mast Cell Disorders, treating children with recurrent infections, and Spirometry. 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Tennessee Society of Allergy, Asthma and Immunology.  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of this meeting, learners should be able to:

1. Utilize new therapies to treat atopic dermatitis.
2. Confidently select the best biologic therapy for severe asthma patients.
3. Implement oral peanut immunotherapy in their practice.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible compnaies have been mitigated.

Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Course opens: 
08/11/2023
Course expires: 
12/31/2023
Event starts: 
08/11/2023 - 3:30pm CDT
Event ends: 
08/13/2023 - 11:30am CDT
Add to calendar: 
Rating: 
5

TSAAI 2023 Annual Meeting
Dollywood’s DreamMore Conference Center, Pigeon Forge, TN
August 11-13, 2023

Friday, August 11, 2023
3:30 – 5:00 pm    Exhibitors setup & Check-In                    
6:15 – 7:00 pm    Welcome reception         
    
Saturday, August 12, 2023
7:15 – 7:45 am    Attendee Check-In
7:15 – 7:45 am    Breakfast & Exhibits                               
7:45 – 8:00 am    Introduction, Karthik Krishnan, MD

8:00 – 9:00 am    Peanut AIT (Who, Why, and How), Richard Wasserman, MD
Q & A

9:00 – 10:00 am    Update of Eosinophilic Esophagitis and Role of Biologic Therapy, Jay Lieberman, MD                
Q & A    

10:00 – 10:30 am Break & exhibits    

10:30 – 11:30 am An Iconoclastic Review of Spirometry: A New Approach to Interpretation, John Kelso, MD                
Q & A

11:30 – 12:30 pm How Do We Define Remission in Asthma and Do Biologics Achieve That in Our Patients?, Nicole Chase, MD
Q & A

1:00 pm    Non-CME Lunch & Learn provided by Takeda, “Hereditary Angioedema (HAE): Navigating Family Dynamics for Attack Prevention” , Douglas Lotz, MD

Sunday, August 13, 2023
7:15 – 8:00 am    Breakfast & Exhibits                                
8:00 – 9:00 am    Update on Current and Emerging Therapies for Atopic Dermatitis, Mark Boguniewicz, MD 
Q & A

9:00 – 10:00 am    Anaphylaxis, Mast Cell Disorders or Something Else, Anne Maitland, MD
Q & A

10:00 – 10:30 am  Break & Exhibits

10:30 – 11:30 am  Approach to the Child with Recurrent Infections: When to Worry and What to Do, Monica Lawrence, MD
Q & A

11:30 am Meeting adjourn
*please stay for a short business meeting & door prize drawing!

Disclosure Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

All relevant financial relationships with inelgible companies have been mitigated.

Mark Boguniewicz, MD, Speaker
Advisor: Regeneron, Sanofi Genzyme, AbbVie, LEO Pharma, Lilly, Pfizer, Amgen, Incyte, Janssen
Researcher: Regeneron, Sanofi Genzyme, Incyte
        
Nicole Chase, MD, Speaker
Advisor: Amgen, AstraZeneca, ARS, Genentech, Novartis, Regeneron, Sanofi, GlaxoSmithKline, Hikma
Consultant: Regeneron, Sanofi
Speaker: Amgen, AstraZeneca, ARS, Incyte, Regeneron, GlaxoSmithKline
Independent Contractor: AstraZeneca, Genentech
 
Monica Lawrence, MD, Speaker
Advisor: Horizon Therapeutics, Enzyvant Therapeutics
Researcher: Regeneron, GSK, CSL Behring

Jay Lieberman, MD, Speaker
Advisor: Aquestive, ALK
Consultant: ALK, Siolta, AbbVie
Researcher: DBV, Regeneron, Novartis
 
Anne Maitland, MD, Speaker
Speaker: Blueprint Medicines
 
Richard Wasserman, MD, Speaker
Consultant: Aimmune, CSL Behring, Grifols, Takeda
Researcher: Cour Pharmaceuticals, Takeda
Speaker: CSL Behring, GSK, Grifols, Takeda
Stock: Belhaven Biopharma


John Kelso, MD, Speaker: No relevant financial relationships with ineligible companies to disclose
Karthik Krishnan, MD, Program Chair and Physician Planner: No relevant financial relationships with ineligible companies to disclose
Michelle Kittle, Meeting Coordinator: No relevant financial relationships with ineligible companies to disclose

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Please login or create an account to take this course.